ArticleInternational dental journal2026
Porphyromonas gingivalis OMVs Activate Macrophage-Hepatic Stellate Cells via Thbs1/TGF-β Signalling in NAFLD.
Article in International dental journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review: Porphyromonas gingivalis Outer Membrane Vesicles From Pathogenesis to Therapeutic Implications.International dental journal · 2026Pooled it
- Periodontitis and Chronic Liver Disease: Mechanistic Insights Focusing onMicroorganisms · 2026Review
- Periodontitis and MASLD: a narrative review of the direct oral-hepatic pathway.Frontiers in cellular and infection microbiology · 2026Review
- Mechanisms underlying the role of the oral-gut-liver axis in the promotion of liver fibrosis by periodontal disease: an interacting network of inflammation, microbiota, and barrier function.Frontiers in cellular and infection microbiology · 2026Review
- The role of thrombospondin-1 in dermatological conditions.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesNonalcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver conditions worldwide, and periodontitis (PD) may be an independent risk factor for the development and progression of NAFLD. However, the underlying mechanisms of how periodontitis promotes the progression of NAFLD remain unclear.
methodsThis study examined the correlation between periodontitis and NAFLD through epidemiological, pathological, and serological analysis. Periodontitis and NAFLD models were established in mice to investigate the role of outer membrane vesicles (OMVs) of Porphyromonas gingivalis (P. gingivalis) in hepatic steatosis. An in vitro study was conducted to confirm the effect of P. gingivalis OMVs on activation of macrophages (MΦs) and hepatic stellate cells (HSCs).
resultsThe incidence of patients with PD and NAFLD was significantly higher than those with NAFLD only, and this proportion was positively related to the severity of PD. In vivo, P. gingivalis OMVs promoted hepatic injury and steatosis in NAFLD induced by a high-fat diet. In vitro, P. gingivalis OMVs activated HSCs through MΦs phenotype switching from M0 toward M1. Mechanistically, MΦs primed by P. gingivalis OMVs activated HSCs via thrombospondin-1 (Thbs1)/transforming growth factor-β (TGF-β) signalling, contributing to the liver fibrosis of NAFLD. Inhibition of Thbs1 can downregulate TGF-β signalling, preventing the progression of NAFLD promoted by P. gingivalis OMVs.
conclusionOverall, this study verified the correlation between NAFLD and periodontitis and provides novel insights into the vital role of P. gingivalis OMVs in activation of macrophage-hepatic stellate cells through Thbs1/TGF-β signalling pathway in the context of NAFLD and periodontitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.